Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Understanding women's knowledge and perceived benefits of vaginal birth and caesarean section: A multi-country survey from the QUALI-DEC project.

Women and birth : journal of the Australian College of Midwives·2026

Same author

Trial trustworthiness assessment: commentary on the Cochrane 2025 systematic review on calcium supplementation during pregnancy.

Reproductive health·2026

Same author

Revisiting the Epistemological Foundations of Evidence-Based Medicine.

Journal of evaluation in clinical practice·2026

Same author

Efficacy and Safety of Cannabis Derivates and Their Synthetic Analogs. Overview of Systematic Reviews.

Phytotherapy research : PTR·2026

Same author

Medullary thyroid carcinoma and RET molecular testing: A virtual tumor board on clinical decision-making.

CA: a cancer journal for clinicians·2026

Same author

The real-world evidence debate: why proper terminology matters.

Journal of clinical epidemiology·2026

Search research articles

Related Experiment Video

Updated: Jul 28, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Alemtuzumab for multiple sclerosis.

Rachel Riera^1,2,3, Maria Regina Torloni⁴, Ana Luiza C Martimbianco^1,2,3,5

¹Cochrane Brazil Rio de Janeiro, Petrópolis Medical School, Petrópolis, Brazil.

The Cochrane Database of Systematic Reviews

|June 5, 2023

Summary

Alemtuzumab may improve relapse-free survival and reduce disability in multiple sclerosis (MS) patients compared to interferon beta-1a. However, the evidence is of low certainty, and adverse events were common with both treatments.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jul 28, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

Neurology
Immunology
Pharmacology

Background:

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
Current treatments aim to manage exacerbations and slow disability progression.
No existing therapy fully achieves these goals safely and effectively.

Purpose of the Study:

To evaluate the efficacy and safety of alemtuzumab in treating multiple sclerosis.
To compare alemtuzumab with placebo, other active drugs, or different regimens of alemtuzumab.

Main Methods:

Conducted a systematic review of randomized controlled trials (RCTs).
Included three RCTs with 1713 participants comparing alemtuzumab to interferon beta-1a.
Assessed outcomes including relapse-free survival, disease progression, adverse events, and disability.

Main Results:

Alemtuzumab demonstrated potential improvements in relapse-free survival and sustained disease progression-free survival at 36 months.
A slight reduction in disability was observed with alemtuzumab.
The proportion of participants experiencing adverse events was similar between alemtuzumab and interferon beta-1a groups.

Conclusions:

Alemtuzumab may offer benefits in managing relapsing-remitting MS compared to interferon beta-1a.
The certainty of evidence for these findings is low to very low.
Further research is needed to fully understand the long-term benefits and risks.